AAD 2020 – Leo’s eczema wildcard proves tame

Being private, Leo Pharma has managed to keep tralokinumab somewhat under wraps, making it an unknown in the Sanofi/Regeneron-dominated dermatitis space. When results of three pivotal studies of the anti-IL-13 MAb were toplined late last year, the lack of actual data prompted suspicions that they were less than knockout. So it has proved.